First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay - Lp(a) SRM 2B

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 6, 2004, Pages 670-676

  Dati, Francesco ^a   Tate, Jillian R ^b   Marcovina, Santica M ^c   Steinmetz, Armin ^d   Berg, K ^e   Couderc, R ^e   Kostner, G M ^e   Rifai, N ^e   Sakurabayashi, I ^e   Tate, J R ^e  

^a IVD Consulting   (Germany)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e NONE

Author keywords

International reference reagent; Lipoprotein(a); Master calibrators; Metrological traceability; Standardization

Indexed keywords

LIPOPROTEIN A; REAGENT;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CALIBRATOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DEVICE; EUROPEAN UNION; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LABORATORY TEST; MEDICAL EXPERT; MEDICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; STANDARD; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EUROPEAN UNION; HUMANS; IMMUNOASSAY; INDICATORS AND REAGENTS; INTERNATIONAL COOPERATION; LIPOPROTEIN(A); REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; WORLD HEALTH ORGANIZATION;

EID: 3242763124     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.114     Document Type: Article

References (18)

1. Marcovina SM, Koschinsky ML. Lipoprotein(a): structure, measurement, and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing, 2nd ed. Washington, DC: AACC Press, 2000:345-85.
2. Cremer P, Nagel D, Mann H, Labrot B, Müller-Berninger R, Elster H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997;129:221-30.
3. Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-61.
4. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. J Am Med Assoc 1994;271:999-1003.
5. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997;17:239-45.
6. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
7. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
8. Cantin B, Gagnon F, Moorjani S, DesPres JP, LaMarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-25.
9. Marburger C, Hambrecht R, Niebauer J, Schoeppenthau M, Scheffler E, Hauer K, et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994;73:742-6.
10. Albers JJ, Marcovina SM. Standardization of Lp(a) measurements. Chem Phys Lipids 1994;67/68:257-63.
11. Couderc R. Report by the Commission lipides-lipoprotéines de la SFBC/ARCOL. Immunodosage de la Lp(a). Etude de la conservation et essai de standardisation. Paris, France: 32éme Dimanches Biologiques de Lariboisière, 1992.
12. Tate J. Lipoprotein(a) standardisation within Australia and New Zealand. Clin Biochem Revs 1994;15:74-81.
13. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995;41:246-55.
14. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 1996;37:2569-85.
15. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-67
16. Tate JR, Rifai N, Berg K, Couderc R, Dati F, Kostner GM, et al. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 1998;44:1629-40.
17. Tate JR, Berg K, Couderc R, Dati F, Kostner GM, Marcovina SM, et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2. Selection and properties of a proposed secondary reference material for lipoprotein(a). Clin Chem Lab Med 1999;37:949-58.
18. Blirup-Jensen S, Johnson AM, Larsen M. Protein standardization IV: value transfer procedure for the assignment of serum protein values from a reference preparation to a target material. Clin Chem Lab Med 2001;39:1110-22.